TMO

Thermo Fisher Scientific Inc.

HealthcareDiagnostics & ResearchNASDAQ

$489.47

+$26.10 (5.33%)today

Conviction

0/ 10

Fair Value$663.96

Upside+35.65%

Signal0

Market Cap$178.3B

52W Range$385.46–$643.99

Next EarningsApr 22

Price History

FAIR VALUE ANALYSISMonte Carlo · 3,000 runs · 99% valid

Fair Value$259.02

Current Price$470.00

Upside / Down-44.9%

P(Undervalued)0.0%

P(20%+ Up)0.0%

P(15%+ Down)97.1%

Fair Value Distribution — percentile bands

0.0% of simulations place fair value above current price

WHAT IS PRICED IN

Revenue-Based Reverse DCF

13.7%/yr

±5.2% · revenue growth to justify current price

FCF-Based Reverse DCF

20.0%/yr

±3.2% · FCF growth to justify current price

THE GAP

Market pricing margin compression or rising capex

KEY VALUE DRIVERS

Spearman correlation — what moves this valuation most

Quick Take

Thermo Fisher Scientific Inc.

Trailing P/E27.0x

Forward P/E17.9x

P/S4.0x

EPS (TTM)$17.75

Analyst Target$663.96

Analyst Upside35.6%

No Eagle analysis yet. Request a full review including conviction score, bull/bear cases, and thesis.

Bull Case

No analysis yet

Bear Case

No analysis yet

Research Feed

sec_10kFeb 28

Conviction: unchanged

TMO FY2025 10-K: Bioproduction Thesis Intact, Tariff Headwinds in Analytical Instruments, Debt Load Rising

TMO delivered .6B in FY2025 revenue (+4%, +2% organic), adjusted EPS .87 (+5%), adjusted operating margin 22.7%. Life Sciences Solutions led growth driven by bioproduction recovery and Solventum filtr...